Table 5.

Incidence and Rate per 1,000 Women-Years (95% CI) of VTEs (Adjudicated Data)

	Bazedoxifene		Raloxifene	Placebo
	20 mg (n = 1886)	40 mg (n = 1872)	60 mg (n = 1849)	(n = 1885)
Any VTE
n	13	13	9	8
Year 1	8	4	2	3
Year 2	4	6	4	2
Year 3	1	3	3	3
Rate	2.8 (1.49, 4.79)	2.9 (1.54, 4.94)	2.0 (0.90, 3.74)	1.7 (0.74, 3.39)
Year 1	4.6 (2.00, 9.14)	2.4 (0.65, 6.09)	1.2 (0.14, 4.29)	1.7 (0.36, 5.05)
Year 2	2.7 (0.73, 6.83)	4.2 (1.53, 9.05)	2.7 (0.74, 6.93)	1.3 (0.16, 4.82)
Year 3	0.7 (0.02, 3.94)	2.2 (0.45, 6.38)	2.1 (0.44, 6.22)	2.1 (0.44, 6.20)
DVT
n	8	9	7	1
Rate	1.7 (0.74, 3.40)	2.0 (0.92, 3.80)	1.5 (0.62, 3.15)	0.2 (0.01, 1.20)
PE
n	3	3	4	4
Rate	0.7 (0.13, 1.89)	0.7 (0.14, 1.95)	0.9 (0.24, 2.24)	0.9 (0.23, 2.20)
RVT
n	2	1	0	3
Rate	0.4 (0.05, 1.56)	0.2 (0.01, 1.24)	0 (0.00, 0.66)	0.7 (0.13, 1.89)
Superficial thrombophlebitis
n	11	18	13	8
Rate	2.4 (1.19, 4.25)	4.0 (2.38, 6.34)	2.9 (1.52, 4.87)	1.7 (0.74, 3.40)

CI, confidence interval; VTE, venous thromboembolic event; DVT, deep vein thrombosis; PE, pulmonary embolism; RVT, retinal vein thrombosis.